Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

DRUG DIVERSION HEARING SEPT. 19 TO HEAR TESTIMONY FROM TWO FELONS from the Atlanta investigation, one who was convicted and another who pled guilty. The witnesses will testify before the House Commerce/Oversight Subcmte., which said it will also hear testimony from a New Jersey private investigator who has probed the internatl. drug diversion market. In August the Justice Dept. announced that it charged 43 individuals and three corporations -- - Cooperative Purchasing Consultants, General Generics, and Pharmacy Resources -- with violations of federal fraud and conspiracy laws, with drug alteration and misbranding, and with interstate transportation of pharmaceuticals obtained by fraud. Individuals who faced charges included Bindley Western VPs Stephen Asher and W. Michael Gemmill and retired Lawrence Pharmaceuticals VP W. Edward Barnhill. The Justice Dept. announcement culminated a two-year nationwide FBI investigation ("The Pink Sheet" Aug. 12, p. 4). The Sept. 19 hearing will be the third Oversight Subcmte. hearing to focus on the drug diversion issue. Fourth and fifth days of hearings to focus on pharmaceutical industry-proposed solutions to the problem are now expected to be scheduled for later this fall, probably in October and November.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts